Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Cash from Financing Activities came in at $8.5 million in Q4 2025, up 11001.54% YoY from N/an in Q4 2024, and down 28.39% on a QoQ basis from $11.9 million in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Cash from Financing Activities data on file, last reported at $8.5 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 11001.54% year-over-year to $8.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.6 million (changed N/A YoY) and the FY2025 annual result came in at $20.6 million, up 6215.26% from the prior year.
- Cash from Financing Activities retreated to $8.5 million in Q4 2025, from $11.9 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $11.9 million in Q2 2025 to a low of $76500.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.68 Mn | 7.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.49 Mn |
| Dec 31, 2025 | 8.49 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 267,200.00 |
| Mar 31, 2025 | 267,200.00 |
| Dec 31, 2024 | 76,500.00 |
| Dec 31, 2024 | 76,500.00 |
| Sep 30, 2024 | 150,000.00 |
| Sep 30, 2024 | 150,000.00 |